The Advisory Committee on Immunization Practices (ACIP) recommendations for Tdap vaccines, authored by Karen R. Broder of the National Center for Immunization and Respiratory Diseases. This statement reviews vaccination policy, describes pertussis epidemiology among adolescents, and summarizes immunogenicity and safety data for two Tdap vaccines licensed in the United States in 2005. It presents specific recommendations for tetanus, diphtheria, and pertussis vaccination among adolescents aged 11-18 years.
Use Cases
- Analyze historical vaccine policy development based on the review of U.S. tetanus, diphtheria, and pertussis vaccination policy.
- Study adolescent pertussis epidemiology based on the description of clinical features and epidemiology mentioned in the description.
- Compare vaccine safety and efficacy profiles based on the summarized immunogenicity and safety data for two Tdap vaccines.
- Model vaccination schedules based on the specific age-based and interval recommendations for Tdap administration.
Strengths
- Provides specific recommendations for a defined age group (adolescents aged 11-18 years).
- Cites concrete licensing dates for two vaccine products (May 3, 2005, and June 10, 2005).
- Summarizes evidence from prelicensure studies on vaccine safety and efficacy.
Limitations
- Row count is unknown, which may limit suitability assessment.
- Column-level documentation is absent; field semantics must be inferred after download.
- Last update date is unknown; freshness unverified.
Provenance
- Source
- Advisory Committee on Immunization Practices (ACIP), National Center for Immunization and Respiratory Diseases
- Collection Method
- Clinical guideline and policy recommendation document.
- Time Range
- Focuses on evidence and recommendations circa 2005.
- Geography
- United States